Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. [PDF]
, 2019 Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming.
Canter, Robert J +2 more
core +2 more sources
Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer [PDF]
, 2023 Natural killer (NK) cells are attractive effectors for adoptive immunotherapy of cancer. Results from first-in-human studies using chimeric antigen receptor (CAR)-engineered primary NK cells and NK-92 cells are encouraging in terms of efficacy and safety.
Anastasia Kurzyukova +21 more
core +1 more source
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy [PDF]
, 2019 Natural killer (NK) cells are lymphocytes of the innate immune response characterized by their role in the destruction of tumor cells. Activation of NK cells depend on a fine balance between activating and inhibitory signals mediated by different ...
Alonso, Corona +12 more
core +1 more source
CAR-NK cell therapy for glioblastoma: what to do next? [PDF]
, 2023 Glioblastoma is a malignant tumor with the highest morbidity and mortality in the central nervous system. Conventional surgical resection combined with radiotherapy or chemotherapy has a high recurrence rate and poor prognosis.
Hongxin Deng +3 more
core +1 more source
Outsmarting trogocytosis to boost CAR NK/T cell therapy
Molecular Cancer, 2023 AbstractChimeric antigen receptor (CAR) NK and T cell therapy are promising immunotherapeutic approaches for the treatment of cancer. However, the efficacy of CAR NK/T cell therapy is often hindered by various factors, including the phenomenon of trogocytosis, which involves the bidirectional exchange of membrane fragments between cells. In this review,
Faezeh Ramezani +6 more
openaire +3 more sources
Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T [PDF]
, 2023 In recent decades, immune checkpoint blockade and chimeric antigen receptor T cell (CAR-T) therapy are two milestone achievements in clinical immunotherapy. However, both show limited efficacies in most solid neoplasms, which necessitates the exploration
Hua, Yuze +8 more
core +1 more source
Off-the-Shelf CAR-NK Cells for Cancer Immunotherapy [PDF]
Cell Stem Cell, 2018 CAR-T therapy has shown great success treating blood cancers, but drawbacks include high manufacturing costs and potentially fatal toxicities such as cytokine release syndrome. In this issue of Cell Stem Cell, Li et al. (2018) describe how engineered iPSC-derived NK cells armed with NK-tailored CAR constructs (CAR-iPSC-NK cells) provide better options ...
Elizabeth L, Siegler +3 more
openaire +2 more sources
Targeting leukemia stem cells in the bone marrow niche [PDF]
, 2018 The bone marrow (BM) niche encompasses multiple cells of mesenchymal and hematopoietic origin and represents a unique microenvironment that is poised to maintain hematopoietic stem cells.
Bertaina +13 more
core +2 more sources
Next Generation CD44v6-Specific CAR-NK Cells Effective against Triple Negative Breast Cancer [PDF]
, 2023 There is a medical need to develop new and effective therapies against triple-negative breast cancer (TNBC). Chimeric antigen receptor (CAR) natural killer (NK) cells are a promising alternative to CAR-T cell therapy for cancer.
Blohmer, Jens-Uwe +7 more
core +1 more source
Cancer Immunotherapy: Make Way for CAR NK [PDF]
Cancer Discovery, 2020 Abstract Having shown preclinical promise, the first clinical data are now in on natural killer cells equipped with a chimeric antigen receptor targeting CD19. Albeit in a small number of patients so far, the experimental immunotherapy has elicited a high response rate with little to no toxicity.
openaire +1 more source